Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 3.27M | 3.94M | 15.53M | 13.91M | 4.36M | 0.00 |
Gross Profit | 1.99M | 1.32M | 12.46M | 10.23M | -99.79M | -3.33M |
EBITDA | -84.50M | -89.15M | -85.06M | -93.91M | -124.54M | -105.06M |
Net Income | -53.26M | -131.21M | -87.68M | -96.05M | -128.33M | -108.54M |
Balance Sheet | ||||||
Total Assets | 150.70M | 70.09M | 151.53M | 146.69M | 235.37M | 265.30M |
Cash, Cash Equivalents and Short-Term Investments | 137.86M | 56.94M | 135.70M | 125.83M | 190.73M | 243.51M |
Total Debt | 7.87M | 8.38M | 11.14M | 12.57M | 14.46M | 13.01M |
Total Liabilities | 34.25M | 99.07M | 59.45M | 42.79M | 50.64M | 45.26M |
Stockholders Equity | 116.44M | -28.97M | 92.08M | 103.90M | 184.73M | 220.04M |
Cash Flow | ||||||
Free Cash Flow | -79.01M | -80.87M | -79.02M | -80.33M | -116.55M | -76.33M |
Operating Cash Flow | -78.91M | -80.74M | -79.00M | -79.39M | -115.66M | -74.26M |
Investing Cash Flow | 26.30M | -18.28M | 44.98M | -26.29M | 3.02M | 32.76M |
Financing Cash Flow | 102.12M | 355.00K | 88.33M | 164.00K | 78.68M | 192.35M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
60 Neutral | HK$15.27B | 5.80 | -7.43% | 4.22% | 11.60% | -21.06% | |
57 Neutral | $207.34M | ― | -414.88% | ― | -65.96% | 40.80% | |
53 Neutral | $45.19M | ― | -60.44% | ― | -76.29% | ― | |
42 Neutral | $21.45M | ― | -70.06% | ― | 146.47% | 57.85% | |
41 Neutral | $35.97M | ― | -853.05% | ― | ― | 34.97% | |
35 Underperform | $39.95M | ― | -280.78% | ― | ― | 68.75% | |
30 Underperform | $45.58M | ― | -2880.11% | ― | ― | 31.09% |
On June 25, 2025, Aligos Therapeutics, Inc. held its Annual Meeting of Stockholders where significant amendments to the company’s Certificate of Incorporation were approved. These amendments included increasing the number of authorized shares of voting common stock from 20 million to 100 million and non-voting common stock from 800,000 to 15.8 million. These changes, effective immediately upon filing with the Secretary of State of Delaware, are expected to impact the company’s capital structure significantly. Additionally, stockholders voted on five proposals, including electing three Class II directors and ratifying Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (ALGS) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on Aligos Therapeutics stock, see the ALGS Stock Forecast page.